FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology, particularly to genetic engineering, and may be used in preparing drugs for hepatitis C. What has been offered is using a pegylated methionine-containing form of N-terminal truncated IL-29 variant with a substituted cysteine residue in a position corresponding to position 171 of an amino acid sequence of a wild-type mature protein expressed in a heterologous system in the form of high homogenous preparations when preparing a drug for hepatitis C.
EFFECT: invention may be used in preparing the drugs for hepatitis C.
3 cl, 37 tbl, 45 ex
| Title | Year | Author | Number |
|---|---|---|---|
| POLYPEPTIDE WITH ANTIVIRAL ACTIVITY, ITS PRODUCTION AND USE | 2004 |
|
RU2372356C2 |
| INTERFERON-LIKE PROTEIN ZCYTO21 | 2001 |
|
RU2292394C2 |
| ISOLATED SOLUBLE IL-20 RECEPTOR (VARIANTS) | 2000 |
|
RU2279441C2 |
| ANTIBODIES DIRECTED AGAINST IL-17 | 2011 |
|
RU2595385C2 |
| IL-4 AND/OR IL-13 BINDING ANTIBODIES AND USING THEM | 2008 |
|
RU2580049C2 |
| ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS | 2011 |
|
RU2533809C9 |
| MODIFIED ANTAGONIST OF RECEPTOR IL-4 AND PURIFIED POLYNUCLEOTIDE INTENDED FOR ITS PRODUCTION | 2004 |
|
RU2389796C2 |
| ANTAGONISTIC ANTIBODIES AGAINST THE IL-7 RECEPTOR AND METHODS | 2014 |
|
RU2653430C2 |
| IL-31 MONOCLONAL ANTIBODIES AND METHODS OF USING | 2006 |
|
RU2444528C2 |
| SELECTIVE AGONISTS AND ANTAGONISTS OF IL-2 | 1999 |
|
RU2235729C2 |
